{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:37:34Z","timestamp":1781764654289,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Transplant."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Cardiac Allograft Vasculopathy (CAV), a process of vascular damage accelerated by antibody-mediated rejection (AMR), is one of the leading causes of cardiac transplant failure. Proteasome inhibitors (PIs) are utilized to treat AMR, however PI-associated toxicity limits their therapeutic utility. Novel immunoproteasome inhibitors (IPIs) have higher specificity for immune cells and have not been investigated for AMR in cardiac transplant patients. We sought to evaluate IPI effect on AMR in a murine cardiac transplant model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fully MHC mismatched C57BL\/6 to huCD52Tg heterotopic heart transplantations were performed. Recipients were treated with alemtuzumab (10\u2005\u00b5g, IP) on days \u22122, \u22121, 2, and 4 and anti-CD25mAb (PC61, 100\u2005\u00b5g, IP) on day 7 to accelerate AMR with or without IPI (ONX-0914,15\u2005mg\/kg, SQ), administered on transplant day and three times a week thereafter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Animals without IPI gradually developed post-transplant donor-specific antibody (DSA) and showed a significantly elevated DSA level compared to animals receiving IPI. (TFXM 48.86 vs. 14.17; <jats:italic>p<\/jats:italic>\u2009=\u20090.0291, BFXM 43.53 vs. 6.114; <jats:italic>p<\/jats:italic>\u2009=\u20090.0031). Accordingly, H&amp;amp;E staining of allograft showed reduced evidence of AMR with IPI compared to controls (<jats:italic>P<\/jats:italic>\u2009=\u20090.0410). Notably, increased mortality was observed in the IPI treated group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrated the ability of ONYX-0914, an IPI, to control post-transplant DSA production and the AMR development in a heart transplant model. However, IPI-resistant DSA production was also observed and increased mortality with IPI therapy raises concerns about potential toxicity. Further investigation is warranted to assess the utility and potential risk associated with the use of IPI as a post-transplant maintenance immunosuppression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frtra.2024.1494455","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:19:23Z","timestamp":1734329963000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunoproteasome inhibition reduces donor specific antibody production and cardiac allograft vasculopathy in a mouse heart transplantation model"],"prefix":"10.3389","volume":"3","author":[{"given":"Allison M.","family":"Schwalb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"DeLaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Ladowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janghoon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Belloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Knechtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kwun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3978\/j.issn.2072-1439.2015.01.46","article-title":"Long-term outcome following heart transplantation: current perspective","volume":"7","author":"Wilhelm","year":"2015","journal-title":"J Thorac Dis"},{"key":"B2","first-page":"319","article-title":"Cardiac allograft vasculopathy: a review","volume":"48","author":"Ramzy","year":"2005","journal-title":"Can J Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.healun.2019.08.004","article-title":"The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult heart transplantation report\u20142019; focus theme: donor and recipient size match","volume":"38","author":"Khush","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.transproceed.2004.05.036","article-title":"Metaanalysis of statins and survival in de novo cardiac transplantation","volume":"36","author":"Mehra","year":"2004","journal-title":"Transplant Proc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.healun.2016.04.007","article-title":"The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection","volume":"35","author":"Clerkin","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ajt.13529","article-title":"Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection","volume":"16","author":"Loupy","year":"2016","journal-title":"Am J Transplant"},{"key":"B7","first-page":"1599","article-title":"Cardiac graft vascular disease. Nonselective involvement of large and small vessels","volume":"56","author":"Russell","year":"1993","journal-title":"Transplantation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.healun.2009.04.035","article-title":"Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection","volume":"28","author":"Kfoury","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/MOT.0000000000000754","article-title":"Antibody-medicated rejection after heart transplantation: diagnosis and clinical implications","volume":"25","author":"Nguyen","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors\u2014molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J Cell Mol Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (velcadetrade mark) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"B13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.kint.2017.09.023","article-title":"Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation","volume":"93","author":"Li","year":"2018","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/MOT.0b013e328330f304","article-title":"Proteasome inhibition for antibody-mediated rejection","volume":"14","author":"Everly","year":"2009","journal-title":"Curr Opin Organ Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fmicb.2015.00021","article-title":"The immunoproteasome and viral infection: a complex regulator of inflammation","volume":"6","author":"McCarthy","year":"2015","journal-title":"Front Microbiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/oxfordjournals.jbchem.a124327","article-title":"Interferon-gamma induces different subunit organizations and functional diversity of proteasomes","volume":"115","author":"Aki","year":"1994","journal-title":"J Biochem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"919036","DOI":"10.3389\/fcvm.2022.919036","article-title":"Vascular rejection in cardiac allograft vasculopathy: impact on graft survival","volume":"9","author":"Nair","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.kint.2018.10.022","article-title":"Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors","volume":"95","author":"Li","year":"2019","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"E8425","DOI":"10.1073\/pnas.1618548114","article-title":"Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice","volume":"113","author":"Karreci","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1111\/j.1600-6143.2012.04181.x","article-title":"Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment","volume":"12","author":"Kwun","year":"2012","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.4049\/jimmunol.162.6.3663","article-title":"Elimination of the immunogenicity of therapeutic antibodies","volume":"162","author":"Gilliland","year":"1999","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.4049\/jimmunol.179.12.8016","article-title":"Altered distribution of H60 minor H antigen-specific CD8T cells and attenuated chronic vasculopathy in minor histocompatibility antigen mismatched heart transplantation in Cxcr3-\/- mouse recipients","volume":"179","author":"Kwun","year":"2007","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1111\/ajt.13789","article-title":"Rapamycin interferes with postdepletion regulatory T cell homeostasis and enhances DSA formation corrected by CTLA4-ig","volume":"16","author":"Oh","year":"2016","journal-title":"Am J Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/TP.0b013e3181b96646","article-title":"Overcoming chronic rejection-can it B?","volume":"88","author":"Kwun","year":"2009","journal-title":"Transplantation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00251-018-1084-0","article-title":"On the role of the immunoproteasome in transplant rejection","volume":"71","author":"Basler","year":"2019","journal-title":"Immunogenetics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1399-3046.2011.01543.x","article-title":"Proteasome inhibitor therapy for antibody-mediated rejection","volume":"15","author":"Woodle","year":"2011","journal-title":"Pediatr Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.healun.2022.10.015","article-title":"The international society for heart and lung transplantation (ISHLT) guidelines for the care of heart transplant recipients","volume":"42","author":"Velleca","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S468","DOI":"10.1016\/j.healun.2019.01.1192","article-title":"Use of bortezomib in the treatment of antibody mediated rejection (AMR) in pediatric heart recipients","volume":"38","author":"Otero","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e15132","DOI":"10.1111\/ctr.15132","article-title":"Reduction of HLA donor specific antibodies in heart transplant patients treated with proteasome inhibitors for antibody mediated rejection","volume":"37","author":"Horn","year":"2023","journal-title":"Clin Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-020-00381-4","article-title":"Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients","volume":"10","author":"Fotiou","year":"2020","journal-title":"Blood Cancer J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1556\/1886.2017.00025","article-title":"Low neurotoxicity of ONX-0914 supports the idea of specific immunoproteasome inhibition as a Side-effect-limiting. Therapeutic Strategy","volume":"7","author":"von Brzezinski","year":"2017","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1078155215588630","article-title":"Fatal pulmonary toxicity due to carfilzomib (kyprolis)","volume":"22","author":"Lataifeh","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071577","article-title":"Immunoproteasome function in normal and malignant hematopoiesis","volume":"10","author":"Tubio-Santamaria","year":"2021","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.3389\/fimmu.2018.02323","article-title":"IL-21 biased alemtuzumab induced chronic antibody-mediated rejection is reversed by LFA-1 costimulation blockade","volume":"9","author":"Kwun","year":"2018","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S410","DOI":"10.1016\/j.healun.2022.01.1033","article-title":"Significant reduction of donor specific antibodies in heart transplant recipients treated with proteasome inhibitors for antibody mediated rejection","volume":"41","author":"Horn","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/ki.2011.502","article-title":"Proteasome inhibitor-based therapy for antibody-mediated rejection","volume":"81","author":"Walsh","year":"2012","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/bloodadvances.2017010991","article-title":"Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates","volume":"1","author":"Kwun","year":"2017","journal-title":"Blood Adv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"101100","DOI":"10.1016\/j.blre.2023.101100","article-title":"Proteasome inhibition in combination with immunotherapies: state-of-the-art in multiple myeloma","volume":"61","author":"Kegyes","year":"2023","journal-title":"Blood Rev"},{"key":"B40","article-title":"Zetomipzomib demonstrates favorable long-term safety and tolerability profile without signs of immunosuppression: results from the PRESIDIO study and its open-label extension study in patients with dermatomyositis and polymyositis","author":"Aggarwal","year":"2023"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1038\/bcj.2017.56","article-title":"A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma","volume":"7","author":"Mitra","year":"2017","journal-title":"Blood Cancer J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist Updat"},{"key":"B43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ajt.15634","article-title":"Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells","volume":"20","author":"Woodle","year":"2020","journal-title":"Am J Transplant"}],"container-title":["Frontiers in Transplantation"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2024.1494455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:19:27Z","timestamp":1734329967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2024.1494455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":43,"alternative-id":["10.3389\/frtra.2024.1494455"],"URL":"https:\/\/doi.org\/10.3389\/frtra.2024.1494455","relation":{},"ISSN":["2813-2440"],"issn-type":[{"value":"2813-2440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1494455"}}